Dr. Joshua W. Osbun, MD

Dr. Osbun practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Osbun's NPI, 1316139793, was assigned on August 9, 2007. Dr. Osbun graduated from University of Texas Southwestern Medical School at Dallas in 2007. Dr. Osbun holds Missouri license 2016020759.

Dr. Osbun's primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Osbun also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Osbun's primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Osbun is also affiliated with Missouri Baptist Medical Center. The medical group on file is Emory Clinic. Dmand AI also links Dr. Osbun to 3 more hospitals, 2 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Osbun practices, 6 sites in all. Vendor and product names are available with a free account.

Neurological surgery is Dr. Osbun's primary specialty in the NPI Registry, under taxonomy code 207T00000X. Dr. Osbun is licensed in Missouri.

CMS data shows 583 Medicare services from Dr. Osbun across 20 procedure codes in 2024, for 288 Medicare patients. Medicare paid $81,251 for them.

CMS counts 288 Medicare patients who saw Dr. Osbun in 2024. The largest group is 65 to 74, with 132 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 1.65, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Osbun's median patient age at 70, with 60% women.

In 2024, Dr. Osbun wrote 383 Medicare Part D claims for 144 patients. 94% of them were for generic drugs. CMS names the drug for 267 of them, across 11 drugs with 11 or more claims each, at $8,984 in total drug cost. In 2023, CMS named 205 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Osbun for performance year 2024, reported as part of a group. Dr. Osbun accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Osbun as offering telehealth.

Laminectomy or laminotomy (partial removal of spine bones): 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 123 papers to Dr. Osbun, published from 2011 to 2025. 2024 was the busiest year, with 20. The most frequent topics are Endovascular Procedures, Thrombectomy and Intracranial Aneurysm. Dr. Osbun has published most often in J Neurointerv Surg. Dr. Osbun's most frequent co-authors are Michael Robert Levitt, MD, Alejandro Marin Spiotta, MD and Adam J. Polifka, MD.

Dmand AI links Dr. Osbun to 4 clinical trials, 2 of them phase 1 studies. 2 are still active or recruiting. Conditions studied include Glioblastoma, Astrocytoma and Hematoma, Subdural, Chronic. Washington University School of Medicine sponsors the most, 3.

CMS Open Payments shows 187 general payments to Dr. Osbun from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 55% of the total. Stryker Corporation paid the most, $31,999.

Dr. Osbun graduated from University of Texas Southwestern Medical School at Dallas in 2007.